Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test
2021-05-27 21:00
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis (IPF) shows promising result in early stage clinical test
2021-05-24 16:59
Daewoong showed improved performance both sales and earnings in Q1
2021-05-07 21:00
HanAll Biopharma Reports First Quarter 2021 Financial Results
2021-05-06 21:00
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
2020-11-06 22:00
Daewoong Pharmaceutical Partners with Tufts Medical Center for Phase 2 Clinical Trial with Niclosamide
2020-10-29 21:00
Daewoong Pharmaceutical's COVID-19 Treatment Candidate Also Highly Effective against Influenza Virus
2020-10-28 22:36
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
2020-10-27 21:00
Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial
2020-09-29 15:00
Daewoong Pharmaceutical announces Korea's first-ever SGLT2 inhibitor for diabetes treatment
2020-09-28 20:00
Daewoong Pharmaceutical Acquires Halal Certification for 'Easyef' through Daewoong Infion
2020-05-27 10:00
Daewoong Pharmaceutical Unveils Phase 3 Clinical Data of Fexuprazan, A Novel Potassium-competitive Acid Blocker
2020-05-11 08:00
Daewoong Infion obtained World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells
2020-01-09 09:51
Daewoong Pharmaceutical Receives World's First Halal Certification for Biopharmaceutical Product Derived from Animal Cells through Indonesian Joint Venture, Daewoong Infion
2020-01-08 11:00
Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of NABOTA
2019-07-09 11:43
Daewoong Pharmaceutical participated in the IMCAS Asia 2019 to introduce the excellence of BEAUTEM
2019-07-09 11:40
1
2
3